Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer

Quality of life (QL) is an important outcome in clinical trials in oncology. There is currently no valid international QL measure for gastric cancer. This paper describes the development of a QL module for gastric cancer to supplement the European Organization for Research and Treatment of Cancer (E...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2001-05, Vol.37 (8), p.966-971
Main Authors: Vickery, C.W, Blazeby, J.M, Conroy, T, Arraras, J, Sezer, O, Koller, M, Rosemeyer, D, Johnson, C.D, Alderson, D
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Clinical Trials as Topic
EORTC QLQ-C30
EORTC QLQ-STO22
Female
Gastric neoplasm
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Middle Aged
Quality of Life
Questionnaire
Stomach Neoplasms - psychology
Stomach Neoplasms - therapy
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Surveys and Questionnaires - standards
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Quality of life (QL) is an important outcome in clinical trials in oncology. There is currently no valid international QL measure for gastric cancer. This paper describes the development of a QL module for gastric cancer to supplement the European Organization for Research and Treatment of Cancer (EORTC) Quality of life (QLQ-C30) questionnaire. Phases I to III of module development were conducted in the United Kingdom, France, Germany and Spain according to EORTC QL Group guidelines. Twenty relevant QL issues were generated from the literature and interviews with health professionals (n=24) and patients (n=58). This produced a 24 item provisional module. Further testing in 115 patients resulted in the QLQ-STO22, containing 22 questions, conceptualised into five scales and four single items, related to disease symptoms, treatment side-effects and emotional issues specific to gastric cancer. The use of the QLQ-C30 supplemented by the QLQ-STO22 will provide a comprehensive QL measure for international trials in gastric cancer.
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(00)00417-2